Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management
, , , , , , , , , , and | Dec 07, 2017
About this article
Article Category: Research Article
Published Online: Dec 07, 2017
Page range: 1 - 6
Received: Sep 11, 2017
Accepted: Nov 05, 2017
DOI: https://doi.org/10.1515/raon-2017-0055
© 2018 Bojan Tepes, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P. Nyssen, Maria G. Donday, Colm O’Morain, Francis Megraud, Adrian G McNicholl, Javier P. Gisbert
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Second line treatment results for treatment regimens with more than 15 patients
| mITT | PP | |||||
|---|---|---|---|---|---|---|
| Treatment | N | Success % | (95% C.I.) | N | Success % | (95% C.I.) |
| Amoxicillin, Levofloxacin, PPI, 14 days | 70 | (78.8%–94.6%) | 65 | (85.3%–98.3%) | ||
| Amoxicillin, Levofloxacin, PPI, 10 days | 24 | (78.6%–100%) | 23 | (85.7%–100%) | ||
| Amoxicillin, Metronidazole, PPI, 7 days | 18 | (21.1%–68.4%) | 17 | (23.1%–72.2%) | ||
| Amoxicillin, Metronidazole, PPI, 10 days | 16 | (68.4%–100%) | 15 | (77.8%–100%) | ||
Helicobacter pylori antibiotic resistance
| Antibiotic | First treatment (95% C.I.) | Second treatment (95% C.I.) | Third treatment (95% C.I.) | Fourth treatment | Fifth treatment | |||
|---|---|---|---|---|---|---|---|---|
| No resistance | 62.5% | (50.0%–75.4%) | 6.1% | (0%–15.6%) | 14.3% | (0%–36.4%) | 0% | 0 |
| Nitroimidazole | 28.6% | (16.7%–40.8%) | 45.5% | (28.1%–63.0%) | 57.1% | (30.0%–83.3%) | 100% | 100% |
| Clarithromycin | 14.3% | (5.7%–24.2%) | 87.9% | (75.7%–97.3%) | 85.7% | (63.6%–100%) | 100% | 100% |
| Amoxicillin | 3.6% | (0%–9.3%) | 0% | 0% | 0% | 0 | ||
| Quinolone | 0% | 6.1% | (0%–15.6%) | 7.1% | (0%–23.5%) | 50% | 0 | |
| Tetracycline | 0% | 3% | (0%–100%) | 7.1% | (0%–23.5%) | 0% | 0 | |
First line treatment results for treatment regimens with more than 15 patients
| mITT | PP | |||||
|---|---|---|---|---|---|---|
| Treatment | N | Success % | (95% C.I.) | N | Success % | (95% C.I.) |
| Clarythromycin, amoxicillin, PPI, 7 days | 664 | (68.6%–75.4%) | 538 | (85.9%–91.3%) | ||
| Clarythromycin, metronidazole, PPI,7 days | 486 | (81.2%–87.5%) | 481 | (82.0%–88.4%) | ||
| Clarythromycin, amoxicillin, PPI, 10 days | 38 | (39.1%–71.1%) | 27 | (60.7%–92.9%) | ||
| Clarythro., amoxicillin., metro., PPI, 7 days | 17 | (70.6%–100%) | 15 | (77.8%–100%) | ||
Demographic data for modified intention to treat (mITT) patient group
| Gender | N (percent) | Minimum Age | Maximum Age | Mean Age | Std. Deviation |
|---|---|---|---|---|---|
| Female | 918 (60.4%) | 18 | 91 | 52.3 | 15.14 |
| Male | 601 (39.6%) | 18 | 88 | 53.3 | 14.76 |
| Total | 1519 | 18 | 91 | 52.7 | 15.0 |
Medical institutions participating in the Slovenian part of EU-HpReg
| Institution | Number | Excluded from analysis (% of hosp. data) Excluded from analysis because of incomplete/invalid data or because the visit was within last year and there is no follow up data yet; | Dropout (%) Patients whose visit was more than a year ago and who had no follow up (dropout = modified intention to treat [mITT] – per protocol [PP]) | |||
|---|---|---|---|---|---|---|
| AM DC Rogaska | 805 | (45.4%) | 146 | (18.1%) | 16 | (2.4%) |
| SB Slovenj Gradec | 464 | (26.2%) | 8 | (1.7%) | 81 | (17.8%) |
| DC Bled | 287 | (16.2%) | 0 | (0%) | 60 | (20.9%) |
| SB Murska Sobota | 73 | (4.1%) | 10 | (13.7%) | 0 | (0%) |
| SB Trbovlje | 68 | (3.8%) | 34 | (50%) | 1 | (2.9%) |
| UKC Ljubljana | 66 | (3.7%) | 50 | (75.8%) | 14 | (87.5%) |
| MC Heliks | 11 | (0.6%) | 7 | (63.6%) | 1 | (25%) |